DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma

Annals of Oncology

Volumn 24, Issue 12, 2013, Pages 3045-3050

  Kim, S ^a,b   Jary, M ^a   Mansi, L ^a   Benzidane, B ^b   Cazorla, A ^a   Demarchi, M ^a,b   Nguyen, T ^a   Kaliski, A ^a   Delabrousse, E ^a   Bonnetain, F ^a,c   Letondal, P ^d   Bosse, J F ^a,c   Valmary Degano, S ^a,c   Borg, C ^a,d  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b Hospital of Belfort Montbeliard   (France)

^c UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^d Plateforme de BioMonitoring   (France)

Author keywords

Anal cancer; DCF; Docetaxel; HPV; Squamous cell carcinoma; Taxane

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; PROTEIN P16; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANUS CARCINOMA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RECTUM RESECTION; RECURRENT DISEASE; SQUAMOUS CELL CARCINOMA; STOMATITIS; TREATMENT OUTCOME; VIRUS DETECTION;

ANAL CANCER; DCF; DOCETAXEL; HPV; SQUAMOUS CELL CARCINOMA; TAXANE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANUS NEOPLASMS; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMAN PAPILLOMAVIRUS 16; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SQUAMOUS CELL; PAPILLOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME;

EID: 84888791950     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt396     Document Type: Article

References (20)

1. Johnson LG, Madeleine MM, Newcomer LM et al. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer 2004; 1012: 281-288.
2. Benson AB, III, Arnoletti JP, Bekaii-Saab T et al. Anal carcinoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012; 104: 449-454.
3. Wilking N, Petrelli N, Herrera L et al. Phase II study of combination bleomycin, vincristine and high-dose methotrexate (BOM) with leucovorin rescue in advanced squamous cell carcinoma of the anal canal. Cancer Chemother Pharmacol 1985; 153: 300-302.
4. Jhawer M, Mani S, Lefkopoulou M et al. Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and bleomycin-CCNU in patients with advanced cancer of the anal canal: an eastern cooperative oncology group study E7282. Invest New Drugs 2006; 245: 447-454.
5. Hainsworth JD, Burris HA, III, Meluch AA et al. Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a phase II trial. Cancer 2001; 923: 642-649.
6. Faivre C, Rougier P, Ducreux M et al. 5-Fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer. Bull Cancer 1999; 8610: 861-865.
7. Glynne-Jones R, Northover JM, Cervantes A. Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl. 5): v87-v92.
8. Peiffert D, Tournier-Rangeard L, Gerard JP et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol 2012; 3016: 1941-1948.
9. Gunderson LL, Winter KA, Ajani JA et al. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol 2012; 3035: 4344-4351.
10. Wahl AF, Donaldson KL, Fairchild C et al. Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nat Med 1996; 21: 72-79.
11. Scheffner M, Werness BA, Huibregtse JM et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 636: 1129-1136.
12. Lorch JH, Goloubeva O, Haddad RI et al. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 2011; 122: 153-159.
13. Valmary-Degano S, Jacquin E, Pretet JL et al. Signature patterns of human papillomavirus type 16 in invasive anal carcinoma. Hum Pathol 2013; 44: 992-1002.
14. Abbas A, Nehme E, Fakih M. Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy. Anticancer Res 2011; 3112: 4637-4640.
15. Alcindor T. Activity of paclitaxel in metastatic squamous anal carcinoma. Int J Colorectal Dis 2008; 237: 717.
16. Lukan N, Ströbel P, Willer A et al. Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. Oncology 2009; 77: 293-299.
17. Golub DV, Civelek AC, Sharma VR. A regimen of taxol, ifosfamide, and platinum for recurrent advanced squamous cell cancer of the anal canal. Chemother Res Pract 2011; 2011: 163736.
18. Lassen P, Eriksen JG, Hamilton-Dutoit S et al. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 2712: 1992-1998.
19. Rischin D, Young RJ, Fisher R et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010; 2827: 4142-4148.
20. Kumar B, Cordell KG, Lee JS et al. EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008; 2619: 3128-3137.